IIT Delhi, AIIMS Delhi to establish Center of Excellence for AI in healthcare
The AI-CoE aims to develop cutting-edge AI-driven solutions to support key national health programmes. This initiative stems from a ₹330 crore grant awarded jointly to both institutions by the Ministry of Education under the 'Make AI in India, Make AI Work for India' initiative, following a rigorous national selection process. The new center will serve as the principal execution body for this ambitious program.
Prof Srinivas emphasized the significance of the initiative, stating, 'This MoU marks the beginning of transformative collaborative research with the potential to reshape healthcare across the country.'
Echoing this vision, Prof. Rangan Banerjee remarked, 'A partnership between AIIMS and IIT Delhi can drive innovation in affordable healthcare. We are proud to shape this national center of excellence and look forward to a measurable impact on Indian lives.'
Leading the initiative from AIIMS Delhi, Dr. Krithika Rangarajan, Chief Project Manager, said, 'As we explore this dynamic intersection of healthcare and technology, our focus remains clear—placing patients at the center and building systems that benefit every citizen.'
From IIT Delhi, Prof. Chetan Arora, Chief Project Manager for the AI-CoE, shared his enthusiasm: 'The CoE will function as a key national and global research hub, leveraging indigenous AI solutions to transform public health. We aim to enhance healthcare delivery, skill development, and accessibility for underserved populations.'
He added, 'This initiative builds upon a legacy of collaboration between IIT Delhi and AIIMS Delhi. Through the AI-CoE, we hope to establish a new benchmark for integrating healthcare with AI research, not just in India but around the world.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
First Post
12 minutes ago
- First Post
Tariff tracker: Can key nations strike tariff deals with the US before August 1 deadline?
US tariff negotiations have heated, as the August 1 deadline looms, with countries scrambling to avoid steep new duties. Deals with the EU, Japan and others have been struck, but talks with South Korea, India, Taiwan, Canada, Mexico and Brazil remain fraught read more A 3D-printed miniature of US President Donald Trump, EU flag and words "15% tariffs" are seen in this illustration taken July 27, 2025. File Image/Reuters US tariff talks with major trading partners have heated as countries scramble to head off sharp duty hikes before the looming August 1 deadline. Many of the tariff increases stem from a package unveiled in April, which outlined that dozens of economies would face higher levies — rising above the existing 10 per cent rate — due to their trade surpluses with the United States. The implementation date for these duties, delayed twice already, is now set for Friday, August 1. STORY CONTINUES BELOW THIS AD In recent weeks, Washington has expanded the list of nations facing these tariffs while simultaneously striking deals with several others, including the European Union, UK, Vietnam, Japan, Indonesia and the Philippines. The agreement reached with the European Union, announced Sunday, imposes a 15 per cent tariff on EU exports to the US — significantly lower than the 30 per cent US President Donald Trump had initially threatened. Where do other US trade talks stand? South Korea Seoul is racing to conclude an accord with Washington, as Tokyo's success in finalising its own deal has 'amped up the pressure for South Korea,' a government source told AFP. Local reports suggested Seoul may propose over $100 billion in investment as part of a broader deal, with likely involvement from major corporations like Samsung and Hyundai Motor. The South Korean government has not confirmed those reports. Officials have, however, detailed plans to boost cooperation in key sectors such as shipbuilding, semiconductors and batteries. National Security Advisor Wi Sung-lak told reporters the two nations were in 'the final and most crucial phase of negotiations' to prevent the 25 per cent tariff proposed by Trump. India Indian Commerce Minister Piyush Goyal told Bloomberg Television on Thursday that he remained confident his country could strike a deal with the United States to stave off Washington's 26 per cent tariff threat. Goyal revealed there were no 'sticking points' in the US-India trade relationship and noted that immigration policies — including rules regarding H-1B visas for skilled workers — had not been part of the ongoing talks. Despite his assurances, media outlets has reported that hopes for even an interim agreement before August 1 had begun to fade. STORY CONTINUES BELOW THIS AD Taiwan Taiwan's Premier Cho Jung-tai said Thursday that negotiators were 'working hard' amid concerns that a harsh tariff rate could damage the island's economy. Vice President Hsiao Bi-khim added that Taipei's team was 'working almost 24 hours a day to achieve trade balance and Taiwan's industrial interests, and even to further deepen cooperation.' Canada, Mexico Though Canada and Mexico escaped Trump's 'reciprocal' tariffs announced in April, products from both nations entering the US are still subject to a separate 25 per cent levy unless they are covered under a North American trade pact. That rate is poised to climb to 30 per cent for Mexican goods on August 1, while Canadian products are set to face a 35 per cent duty. Mexican President Claudia Sheinbaum said her government was 'doing everything' it could to stop the tariffs and expressed willingness to speak with Trump personally to secure a deal. Trump told reporters on Friday that no agreement with Canada had been reached. Brazil Brazil is bracing for what could amount to a virtual trade embargo on its planes, grains and other exports if Trump's threatened 50 per cent tariff is enacted on August 1. Despite the fact that the US runs a trade surplus with Brazil — Latin America's largest economy — the country was not initially expected to be targeted under Trump's 'reciprocal' tariff plan. Trump has made no effort to conceal the political undertones of the move, pointing to a judicial 'witch hunt' against his right-wing ally, former president Jair Bolsonaro, when announcing the tariff rate. STORY CONTINUES BELOW THIS AD The overtly political backdrop makes a last-minute resolution appear increasingly unlikely. With inputs from AFP
Time of India
25 minutes ago
- Time of India
Tesla "beats" Xiaomi, BYD and Huawei in driving assisted tests in China; CEO Elon Musk says: Due to laws against ...
Tesla tops ADAS performance test on China's highways, outperforming BYD, Xiaomi and Huawei in trials by CCTV and Bytedance's auto unit Dcar. Tesla outperformed Chinese competitors like BYD, Xiaomi, and Huawei in a test of Level 2 advanced driving assistance systems (ADAS) conducted on China's highways. The test, reportedly a collaboration between state television CCTV and Bytedance's auto unit Dcar, evaluated over 20 electric vehicle brands in high-risk highway and urban traffic scenarios. Videos of the test, shared by Dcar, gained significant traction on Chinese social media. Tesla CEO Elon Musk too responded to a post on these tests. Sharing details of these tests, Tesla investor and Model Y owner Sawyer Merritt, wrote, "NEWS: Chinese media tested ADAS in various scenarios, including highways & night driving. @Tesla's vision-based system outperformed emerging Chinese brands like Huawei & Xiaomi, as well as traditional automakers. Even with LiDAR, competitors' ADAS performance lags behind Tesla." Below he shared all the parameters and one-and-a-half-hour video. Elon Musk highlighted on Twitter that Tesla achieved these results despite restrictions on local data training due to U.S. laws prohibiting AI software training in China. "Due to laws against data export, Tesla achieved the top results in China despite having no local training data," Elon Musk said on his Twitter account. Tesla is seeking approval from Chinese regulators to transfer Shanghai-stored data to the US for algorithm development, a situation Musk called a 'quandary.' As per the tests published by TikTok owner Bytedance's auto unit Dcar, Tesla's Model 3 and Model X topped the highway test, passing five out of six scenarios, while BYD's Denza Z9GT and Huawei-backed Aito M9 failed three, and Xiaomi's SU7 passed only one. HIMA, Huawei's auto alliance, declined to comment on the test, per a Weibo post. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Buy Resmed AirSense 11 with flat 20% off ResMed Buy Now Undo A Reuters report quoted Wang Yao, deputy chief engineer at the China Association of Automobile Manufacturers, urging Chinese brands to address the gap with Tesla in autonomous driving technology during a recent Shanghai auto forum. Xiaomi CEO Lei Jun, referencing a Tesla Model Y's autonomous delivery in Texas last month, acknowledged Tesla's industry leadership, stating, 'We will continue to learn.' In late June, Tesla arranged for a Model Y crossover to drive itself from its Texas factory to a customer in downtown Austin some 30 minutes away. The test follows heightened safety concerns in China after a fatal March accident involving a Xiaomi SU7, prompting scrutiny of ADAS marketing. Chinese authorities have banned terms like 'smart driving' and 'autonomous driving' in promotions, and the public security ministry warned of legal and safety risks for drivers relying on these systems. Despite a brief dip in Xiaomi's EV orders post-accident, its new electric SUV saw strong initial demand last month. Tesla's China-made EV sales rose 0.8% year-on-year in June, ending an eight-month decline, though quarterly sales continued to lag amid competition from lower-cost Chinese models. Tesla's ADAS, priced at nearly $9,000 in China, relies solely on cameras and AI, unlike rivals like BYD, which incorporate lidar for enhanced performance. AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Economic Times
31 minutes ago
- Economic Times
India, UK trade pact does not mandate patent term extensions or data exclusivity
Representative image The India-UK free trade agreement (FTA) does not mandate patent term extensions or data exclusivity, which are two common tools of evergreening of patents, according to a commerce ministry document. The move would protect the interests of the domestic generic drugs industry. The UK was demanding for inclusion of "data exclusivity" provision in the agreement. "The FTA does not mandate patent term extensions or data exclusivity -- two common tools of evergreening. India's patent law provisions on patentability criteria under Section 3(d) (of Indian Patent Act) remain fully protected," the ministry said. Section 3(d) of the Indian Patents Act, 1970, restricts patents for already-known drugs unless the new claims are superior in terms of efficacy, while Section 3(b) bars patents for products that are against public interest and do not demonstrate enhanced efficacy over existing products. Certain multinational firms have asked India to amend these laws, which were strongly opposed. The agreement, signed on July 24, may take about a year to come into force. Data exclusivity provides protection to the technical data generated by innovator companies to prove the usefulness of their products. In the pharmaceutical sector, drug companies generate data through expensive global clinical trials to prove the efficacy and safety of their new medicine. By gaining exclusive rights over this data, innovator companies can prevent their competitors from obtaining a marketing licence for low-cost versions during the tenure of this exclusivity. Earlier, India had also rejected a similar demand from the four-nation EFTA bloc in their free trade agreement negotiations. The European Free Trade Association (EFTA) members are Iceland, Liechtenstein, Norway, and Switzerland. The pact was signed in March 2023 and will be implemented later this year. The UK (AstraZeneca and GSK) and Switzerland (Novartis and Roche) have some of the major pharma firms of the world. India's generic drug industry is estimated about USD 25 billion, and the country exports 50 per cent of its produce. An expert said data exclusivity is beyond the provisions of the Trade Related Aspects of Intellectual Property Rights (TRIPS) agreement under the World Trade Organization (WTO). Evergreening of patent rights is a strategy allegedly adopted by the innovators having patent rights over products to renew them by bringing in some minor changes, such as adding new mixtures or formulations. It is done when their patent is about to expire. A patent on the new form gives the innovator company a 20-year monopoly on the drug. "The FTA does not require India to provide patent term extensions for regulatory delays and data exclusivity for pharmaceuticals or agrochemicals," it said, adding that this ensures that generic manufacturers can enter the market without unnecessary delay, once the patent has expired or is challenged. The agreement, it said, does not alter or dilute India's ability to refuse patents for minor modifications of known substances; and prevent frivolous or repetitive patent filings that block generics. "There is no obligation for patent linkage or automatic injunctions either-key tools used to delay generics in other jurisdictions," the ministry said.
